Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637572 · ClinicalTrials.gov registry record · Phase 2
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00637572: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00637572 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00637572, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation
Interventions
- DRUG Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
- DRUG Megestrol acetate oral suspension 40 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637572
The ClinicalTrials.gov registry entry for NCT00637572 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL is the first listed.
NCT00637572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637572 about?
NCT00637572 is a clinical study titled "Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss". Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation
What is the current status of trial NCT00637572?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2004-12. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00637572?
The interventions under investigation include: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL (DRUG), Megestrol acetate oral suspension 40 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00637572?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.